MedTrace Logo

Dexamethasone and Bupivacaine for Pain After Hernia Surgery

NCT07208253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2025-10-06

No results posted yet for this study

Summary

This study looked at whether a combination of two medicines, dexamethasone and bupivacaine, can reduce pain after laparoscopic hernia surgery. A total of 175 patients who had elective total extraperitoneal (TEP) hernia repair were randomly assigned to two groups. One group received a spray of dexamethasone and bupivacaine around the surgical mesh, while the other group did not receive any local treatment.

Pain levels were measured at 3, 6, and 12 hours after surgery using a visual pain scale. The need for additional pain medicine and patient satisfaction were also recorded. Patients who received dexamethasone and bupivacaine reported lower pain scores, needed less extra pain medicine, and were more satisfied with their pain control compared to the control group.

The results suggest that this simple, safe, and low-cost method may help improve pain control and comfort after laparoscopic hernia repair.

Conditions

  • Inguinal Hernia Repair (Not Urgent)

Interventions

DRUG

Bupivacaine + Dexamethasone

20 mg bupivacaine (4 mL of 0.5%) combined with 8 mg dexamethasone, sprayed locally over the mesh and surrounding tissues after placement during laparoscopic TEP hernioplasty.

Sponsors & Collaborators

  • Gürkan Değirmencioğlu

    lead OTHER_GOV

Principal Investigators

  • GÜRKAN DEĞİRMENCİOĞLU, MD · Etlik City Hospital, Department of General Surgery, Ankara,Turkey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-31
Completion
2023-01-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07208253 on ClinicalTrials.gov